Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Paths to Defeating Itch: History, Mechanisms, and Emerging Therapies
Description
The speaker reviews the history and biology of itch, noting that while early thinking focused on histamine and antihistamines, modern understanding shows itch is far more complex and involves strong interactions among the skin barrier, immune system, and nervous system. Peripheral itch, especially in conditions like atopic dermatitis, often begins with barrier damage and microbial changes such as staph-related effects, while central itch remains poorly understood and harder to treat. The talk highlights progress in therapies, including JAK inhibitors and IL-31/other cytokine-targeted approaches, but emphasizes that single-target treatments often fail because itch is driven by multiple pathways and diverse neural/endotypic subtypes. New models using mice, omics, and spatial transcriptomics show keratinocytes, T cells, cytokines like IL-13 and IL-22, and sensory nerves all contribute to disease, and removing nerves can reduce skin inflammation. The speaker also discusses microbiome-based strategies, stress-neural links, and the possibility that reducing stress while enhancing pleasure may help defeat itch.
View moreConclusions
- Itch is no longer viewed as a simple histamine-driven symptom, but as a complex neuroimmune disorder involving skin barrier dysfunction, immune cells, and nerves.
- Peripheral itch is better understood than central itch, and restoring skin homeostasis appears to be a key therapeutic strategy for itch originating in the skin.
- Modern itch biology points to multiple interacting mediators and pathways, making single-target therapies less reliable and combination approaches more promising.
- Atopic dermatitis is heterogeneous and cannot be reduced to a single type 2 immune endotype, which helps explain why some patients respond poorly to current biologics.
- A mouse model combining Staph protease and house dust mite allergen can reproduce important features of human atopic dermatitis, including transcriptomic and cellular endotypes.
- Keratinocytes are active participants in atopic dermatitis and itch, not just passive barrier cells.
- Skin nerves are necessary for full inflammatory and itch responses, and removing nerve input can markedly reduce skin inflammation and T-cell recruitment.
- IL-13- and IL-22-producing T cells emerge in the dermatitis model and may be clinically relevant, supporting IL-22 pathway targeting as a potential treatment strategy.
- The skin microbiome in atopic dermatitis is difficult to modify, since beneficial bacteria do not easily colonize or persist on diseased skin.
- Stress can worsen atopic dermatitis through a sympathetic-eosinophil-neural axis, linking psychological state to skin inflammation and itch.
- Future itch therapies may need to modulate both stress and pleasure-related neural circuits, rather than focusing only on inflammation or histamine.
- The overall direction of the field is toward integrated, multi-target, neuroimmune therapies that address the skin, immune system, nervous system, microbiome, and brain together.
- Ständer & Schmelz. JID 2024.
- Tyler Beck et al. Human dorsal root ganglion-based itch subcluster mapping and pathway analysis via single-nucleus RNA sequencing. JID DOI: 10.1016/j.jid.2026.02.019.#10.1016/j.jid.2026.02.019
- Brunner, Guttman-Yassky 2018.
- Tsoi, Gudjonsson 2019.
- Richard Gallo et al. Journal of Investigative Dermatology (2026) 146, 1157—1160; doi:10.1016/j.jid.2025.09.014.#10.1016/j.jid.2025.09.014
- A sympathetic-eosinophil axis orchestrates psychological stress to exacerbate skin inflammation. Science; cited as Gallo et al. 2026.#10.1126/science.adv5974